- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Despite being the leading cause of death among women, cardiovascular disease is largely unrecognized by female patients, with education and awareness around risk factors and symptoms particularly lacking in women of color. Physicians have also been known to underestimate cardiovascular risks in women who present with a different disease course vs men.
On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women, applicability of current screening and care delivery guidelines for heart health in regards to minority populations, and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen above or through one of these podcast services:
SABCS 2023 Sessions Touch on "Every Aspect of Breast Cancer"
December 4th 2023The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.
Read More
New Data Update Myasthenia Gravis Outcomes for Patients in Australia
December 3rd 2023Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Read More
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More
